This article is more than 5 years old. Information may no longer be current.

VIDEO: Aerie CEO reviews company's recent advances in glaucoma

Issue: October 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the Ophthalmology Innovation Summit here, chairman and chief executive officer of Aerie Pharmaceuticals Vincente Anido Jr., PhD, says "spectacular" progress has been made with regard to two of the company's leading glaucoma products. In September, the company filed a new drug application for Rhopressa (netarsudil), a rho kinase inhibitor that acts on the trabecular meshwork, and "very successful" phase 3 trial results were reported for Roclatan, a product combining Rhopressa and latanoprost.